Trending...
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- Capacity Crunch for Cold Plating? Not Anymore
- Why Philadelphia Homeowners Should Ditch Oil for Natural Gas
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company will release the progress of the next-generation anti-CTLA-4 antibody HBM4003 studies of monotherapy and combination therapy with anti-PD-1 antibody at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 3-7 in Chicago.
Details for the presentations:
Abstract One
Title: A Phase I Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Abstract number: 363712
Publication Format: Poster
Abstract Two:
Title: A Phase I Open-label Study to Evaluate the Safety, Tolerability, PK/PD and Anti-tumor Activity of HBM4003 in Combination with Toripalimab in Subjects with Advanced Melanoma and Other Solid Tumors
Abstract number: 368316
Publication Format: Abstract
"We are extremely pleased to announce the progress of HBM4003 studies at ASCO Annual Meeting 2022. HBM4003 has a remarkable safety and tolerability profile with encouraging anti-tumor efficacy. Given the high therapeutic promise of HBM4003, we are proceeding with multiple global phase Ib/IIa trials in solid tumors. We look forward to bringing this novel therapeutic to cancer patients worldwide." Said Dr. Humphrey Gardner, CMO of Harbour BioMed.
More on illi News
HBM4003 has demonstrated strong efficacy and excellent safety profile. It is believed that this product will have the potential to lead the development of next generation therapy of immuno-oncology, especially combination therapeutics. The Company will continue to be fully committed to advancing the global clinical development project of HBM4003, furthering its global innovation and development strategy in 2022.
Harbour BioMed is developing HBM4003 as part of its broad and innovative immuno-oncology pipeline to address significant unmet medical needs in many solid tumor indications.
About HBM4003
HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. It is the first fully human heavy-chain-only monoclonal antibody entered into clinical stage globally. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 expressing Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combination therapy.
More on illi News
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, HBICE® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
SOURCE Harbour BioMed
Details for the presentations:
Abstract One
Title: A Phase I Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Abstract number: 363712
Publication Format: Poster
Abstract Two:
Title: A Phase I Open-label Study to Evaluate the Safety, Tolerability, PK/PD and Anti-tumor Activity of HBM4003 in Combination with Toripalimab in Subjects with Advanced Melanoma and Other Solid Tumors
Abstract number: 368316
Publication Format: Abstract
"We are extremely pleased to announce the progress of HBM4003 studies at ASCO Annual Meeting 2022. HBM4003 has a remarkable safety and tolerability profile with encouraging anti-tumor efficacy. Given the high therapeutic promise of HBM4003, we are proceeding with multiple global phase Ib/IIa trials in solid tumors. We look forward to bringing this novel therapeutic to cancer patients worldwide." Said Dr. Humphrey Gardner, CMO of Harbour BioMed.
More on illi News
- Chicago: Mayor Brandon Johnson Stands With Congressional Leaders, Meets With Residents About Ongoing ICE Raids
- Predatory Refinancing: How Desperate Homeowners Are Tricked Into Losing Their Equity
- Isringhausen Imports Announces 2025 DRIVE Grant Recipients
- Lokal Media House Earns ServiceTitan Certified Marketer Status
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
HBM4003 has demonstrated strong efficacy and excellent safety profile. It is believed that this product will have the potential to lead the development of next generation therapy of immuno-oncology, especially combination therapeutics. The Company will continue to be fully committed to advancing the global clinical development project of HBM4003, furthering its global innovation and development strategy in 2022.
Harbour BioMed is developing HBM4003 as part of its broad and innovative immuno-oncology pipeline to address significant unmet medical needs in many solid tumor indications.
About HBM4003
HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. It is the first fully human heavy-chain-only monoclonal antibody entered into clinical stage globally. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 expressing Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combination therapy.
More on illi News
- Poised for Major Growth with Strategic Military Orders, Global Expansion, and Groundbreaking Underground Mining Initiative $RMXI
- XRP fever is coming again, WOA Crypto helps the new trend and earns tens of thousands of dollars a day
- Inflation Rebounds Under Tariff Shadow: Wall Street Veteran Kieran Winterbourne Says Macro Signals Matter More Than Market Sentiment
- Vine Prime Community Launches Investor Pathway Program to Build Structured Investor Growth
- Mensa Foundation's New Science Program Encourages Hands-On Discovery
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, HBICE® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
SOURCE Harbour BioMed
Filed Under: Business
0 Comments
Latest on illi News
- WOA Crypto redefines cloud Bitcoin mining, offering free access and instant profit opportunities
- Pepperdine University Malibu, California and Community Partners Recognized with 2025 ReadyCommunities Partnership National Service Award
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
- Regulated Crypto Exchange TZNXG Addresses Core US Market Challenges with Compliance-First Infrastructure
- Unleash Your Inner Seduction at HandPickedSC.com's "The Hot & The Wicked Halloween Soirée"
- GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
- ZapperBox NextGen TV Gateway Receiver Now Testing Support For Secure Whole-Home Content Distribution
- Life as a Dog: P-Wave Press Brings Readers a Heartwarming Memoir of Love, Laughter and Companionship
- NOYA Launches Premium, Design-Forward Training Gear That Belongs at the Center of Your Space
- Research Defense Examines Violence, Illiteracy, Non-Active Fathers, and Low Self-Esteem Among Males
- Investing in Greece: Your Definitive Real-Estate FAQ Guide
- Mayor Brandon Johnson & World Business Chicago Host Chicago Consular Corps Diplomatic Roundtable
- KeysCaribbean Offers 20 Percent Off Seven-Night Stays For Private Home Collection Properties
- Advancing Circular Economy in Automotive ESD Packaging
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- Medcor Expands Telemedicine Access with Telecare Anywhere
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"